干旱区生态环境知识资源中心(Arid): SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry

Arid

DOI	10.1016/j.amjcard.2024.02.021
	SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry
	Jolly, Sanjit S.; Lee, Shun Fu; Mian, Rajibul; Kedev, Sasko; Lavi, Shahar; Moreno, Raul; Montalescot, Gilles; Hillani, Ali; Henry, Timothy D.; Asani, Valon; Storey, Robert F.; Silvain, Johanne; Spratt, James C. S.; d'Entremont, Marc-Andre; Stankovic, Goran; Zafirovska, Biljana; Natarajan, Madhu K.; Sabate, Manel; Shreenivas, Satya; Pinilla-Echeverri, Natalia; Sheth, Tej; Altisent, Omar Abdul-Jawad; Ribas, Nuria; Skuriat, Elizabeth; Tyrwhitt, Jessica; Mehta, Shamir R.
通讯作者	Jolly, SS
来源期刊	AMERICAN JOURNAL OF CARDIOLOGY
ISSN	0002-9149
EISSN	1879-1913
出版年	2024
卷号	220 页码:111-117
英文摘要	Our objective was to evaluate the clinical effectiveness of the SYNERGY stent (Boston Scientific Corporation, Marlborough, Massachusetts) in patients with ST-elevation myocardial infarction (STEMI). The only drug-eluting stent approved for treatment of STEMI by the Food and Drug Administration is the Taxus stent (Boston Scientific) which is no longer commercially available, so further data are needed. The CLEAR (Colchicine and spironolactone in patients with myocardial infarction) SYNERGY stent registry was embedded into a larger randomized trial of patients with STEMI (n = 7,000), comparing colchicine versus placebo and spironolactone versus placebo. The primary outcome for the SYNERGY stent registry is major adverse cardiac events (MACE) as defined by cardiovascular death, recurrent MI, or unplanned ischemia-driven target vessel revascularization within 12 months. We estimated a MACE rate of 6.3% at 12 months after primary percutaneous coronary intervention for STEMI based on the Thrombectomy vs percutaneous coronary intervention alone in STEMI (TOTAL) trial. Success was defined as upper bound of confidence interval (CI) to be less than the performance goal of 9.45%. Overall, 733 patients were enrolled from 8 countries with a mean age 60 years, 19.4% diabetes mellitus, 41.3% anterior MI, and median door-to-balloon time of 72 minutes. The MACE rate was 4.8% (95% CI 3.2 to 6.3%) at 12 months which met the success criteria against performance goal of 9.45%. The rates of cardiovascular death, recurrent MI, or target vessel revascularization were 2.7%, 1.9%, 1.0%, respectively. The rates of acute definite stent thrombosis were 0.3%, subacute 0.4%, late 0.4%, and cumulative stent thrombosis of 1.1% at 12 months. In conclusion, the SYNERGY stent in STEMI performed well and was successful compared with the performance goal based on previous trials. (c) 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/) (Am J Cardiol 2024;220:111 - 117)
英文关键词	drug-eluting stent PCI STEMI
类型	Article
语种	英语
开放获取类型	hybrid
收录类别	SCI-E
WOS记录号	WOS:001237694800001
WOS关键词	BARE-METAL
WOS类目	Cardiac & Cardiovascular Systems
WOS研究方向	Cardiovascular System & Cardiology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/402812
推荐引用方式 GB/T 7714	Jolly, Sanjit S.,Lee, Shun Fu,Mian, Rajibul,et al. SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry[J],2024,220:111-117.
APA	Jolly, Sanjit S..,Lee, Shun Fu.,Mian, Rajibul.,Kedev, Sasko.,Lavi, Shahar.,...&Mehta, Shamir R..(2024).SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry.AMERICAN JOURNAL OF CARDIOLOGY,220,111-117.
MLA	Jolly, Sanjit S.,et al."SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry".AMERICAN JOURNAL OF CARDIOLOGY 220(2024):111-117.